The Experts in FDA and USDA Regulatory Matters
EAS Consulting Group is a leading provider of regulatory compliance solutions to industries regulated by FDA, USDA, and supporting agencies. Our team of consultants provide expert guidance for all of your regulatory requirements.
Food
Learn More
Dietary Supplements
Learn More
Pharmaceuticals
Learn More
Medical Devices
Learn More
Tobacco
Learn More
Cosmetics
Learn More
Veterinary
Learn More
Cannabis
Learn More
Our Services: Consulting • Submissions • Auditing • Training • Legal Support
Learn With Us
Seminars
Transition from Computer System Validation (CSV) to Computer Software Assurance (CSA)
The life science industries, including pharmaceutical, medical device, biotechnology, biological, and tobacco and tobacco-related products continue to embrace new technology to improve delivery of quality products in compliance with FDA. In addition, we’ve seen a trend toward making use of cloud services, Software-as-a-Service (SaaS) solutions, and other technical innovations such as use of Artificial Intelligence (AI), Machine Learning (ML) and Large Language Models (LLMs), such as ChatGPT that have more recently begun to be used more heavily in life science companies.
Webinars
Animal Food GRAS: Unpacking the Essentials
Presented by Dr. Adam Orr and Tim LombardoJune 17, 2026 | 3:00 PM ETThe U.S. is one of the most promising and expansive markets for innovative animal food ingredients. However, accessing the US requires knowledge about its regulatory requirements. Among the regulatory...
On Demand Webinars
Responding to Food and Seafood FDA 483s
When the FDA issues a Form 483 or Warning Letter, your response is critical—and time-sensitive. How you respond can directly impact regulatory outcomes, enforcement risk, and your firm’s credibility.
This webinar will walk through FDA expectations for responding to inspectional observations, along with proven strategies for developing clear, complete, and effective responses. Attendees will gain practical guidance on crafting responses that not only address findings, but also demonstrate control, accountability, and a path to sustained compliance.
Latest News
Drug and Device Corner 2026 May
Reminder that OMUFA user fee payments are due 1 June 2026. The agency allows a 20-day grace period before publishing facilities on the arrears list. Keep in mind, per regulation, drugs manufactured...
FDA Issues Foreign Supplier Verification Program (FSVP) Warning Letters
The FDA recently issued a series of warning letters citing companies for failure to comply with Foreign Supplier Verification Program requirements. In these cases, the FDA said the companies “did...
New FDA Guidance on Infant Formula Protein Efficiency Ratio (PER) Studies
The FDA has issued final guidance for industry on Protein Efficiency Ratio rat bioassay studies used to demonstrate that new infant formulas meet the required “quality factor of sufficient...
Get the Newsletter
Subscribe to EASeNews and join the nearly 20,000 who receive the monthly EASeNews regulatory newsletter.
Need Regulatory Support?
Start the Conversation Today